Crinetics Pharmaceuticals, Inc. (CRNX) — 8-K Filings

8-K Filings (25)

• 8-K Filing — Dec 17, 2025
• Crinetics Pharmaceuticals Files 8-K — Sep 26, 2025 Risk: low
  Crinetics Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting events as of September 25, 2025. The filing includes information related to Regula
• Crinetics Pharmaceuticals Files 8-K — Jun 30, 2025 Risk: low
  Crinetics Pharmaceuticals, Inc. filed an 8-K on June 30, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The f
• 8-K Filing — Jun 26, 2025
• Crinetics Pharmaceuticals Files 8-K on Shareholder Vote — Jun 12, 2025 Risk: low
  Crinetics Pharmaceuticals, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of its security holders on June 11, 2025. The filing det
• Crinetics Pharmaceuticals Files 8-K on Governance Changes — Apr 4, 2025 Risk: medium
  On April 1, 2025, Crinetics Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The f
• Crinetics Pharmaceuticals Announces Board and Executive Changes — Feb 24, 2025 Risk: medium
  Crinetics Pharmaceuticals, Inc. announced on February 21, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the com
• Crinetics Pharmaceuticals Files 8-K — Jan 14, 2025 Risk: low
  On January 14, 2025, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the filing of financial st
• Crinetics Pharmaceuticals Files 8-K — Jan 10, 2025 Risk: low
  On January 10, 2025, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, wit
• Crinetics Pharmaceuticals Announces Director Departure, New CMO — Dec 16, 2024 Risk: medium
  On December 16, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically,
• Crinetics Pharmaceuticals Files 8-K — Dec 9, 2024 Risk: low
  On December 9, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits,"
• Crinetics Pharmaceuticals Appoints New CMO and CSO — Oct 16, 2024 Risk: medium
  Crinetics Pharmaceuticals, Inc. announced on October 10, 2024, the appointment of Dr. Michael R. Levitt as Chief Medical Officer and Dr. David M. Recker as Chie
• Crinetics Pharmaceuticals Files 8-K — Oct 9, 2024 Risk: low
  On October 8, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine u
• Crinetics Pharmaceuticals Files 8-K — Sep 26, 2024 Risk: low
  On September 26, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routin
• Crinetics Pharmaceuticals Announces Executive and Board Changes — Sep 17, 2024 Risk: medium
  Crinetics Pharmaceuticals, Inc. announced on September 13, 2024, changes in its executive team and board of directors. Specifically, Dr. David J. E. Wood was ap
• Crinetics Pharmaceuticals Files 8-K — Jun 21, 2024 Risk: low
  On June 21, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine upd
• Crinetics Pharmaceuticals Files 8-K on Shareholder Votes — Jun 10, 2024 Risk: low
  Crinetics Pharmaceuticals, Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of security holders as of June 7, 2024. The filing detai
• Crinetics Pharmaceuticals Files 8-K — Jun 3, 2024 Risk: low
  On June 3, 2024, Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K report. The filing confirms the company's principal executive offices are located at 6055 L
• Crinetics Pharmaceuticals Files 8-K — May 22, 2024 Risk: low
  On May 22, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits.
• Crinetics Pharmaceuticals Files 8-K for Regulation FD — May 8, 2024 Risk: low
  On May 8, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, indicating that the company is pro
• 8-K Filing — Apr 4, 2024
• Crinetics Pharmaceuticals Appoints New Chief Medical Officer — Mar 19, 2024 Risk: low
  On March 19, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K to disclose the appointment of Dr. David A. R. Gray as Chief Medical Officer, effective March 18
• Novartis to Acquire Crinetics Pharmaceuticals for $2.7B — Mar 12, 2024 Risk: medium
  Crinetics Pharmaceuticals, Inc. announced on March 12, 2024, that it has entered into a definitive agreement to be acquired by Novartis AG. The transaction is v
• Crinetics Pharmaceuticals Files 8-K — Mar 1, 2024 Risk: medium
  On February 27, 2024, Crinetics Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity se
• Crinetics Pharma Files 8-K, Confirms Nasdaq Listing — Jan 8, 2024
  Crinetics Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose its current report status and confirm its registration on the Nasdaq Glob

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX